Method Development for Priority HPHCs in Tobacco Smoke and Smokeless Tobacco Products
Principal Investigator: Cliff Watson / Matt Walters
Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Award Date: 4/1/2011
Institution: Centers for Disease Control and Prevention
Select test methods for specific harmful and potentially harmful constituents (HPHCs) exist; however, FDA wants to develop new, more robust methods for those HPHCs that have not been well characterized. This project involves the development and confirmation of analytical methods and procedures to measure HPHC levels in smoke and smokeless tobacco products. The contracted laboratory will develop high quality, robust methods for constituents in smoke and smokeless tobacco products. Methods may include tandem mass spectrometry (MS-MS), inductively coupled plasma mass spectrometry (ICP-MS), ion chromatography (IC), ultra-performance liquid chromatography mass spectrometry (UPLC-MS), and/or gas chromatography/mass spectrometry (GC/MS). The development and robustness of methods and procedures will ensure that FDA receives high quality and accurate data to inform regulatory decision-making related to HPHCs.